viewAntibe Therapeutics Inc

Antibe Therapeutics targets US$9 billion market with second pipeline drug ATB-352 for severe pain

The Toronto-based company is targeting the postoperative pain sector with ATB-352, a potent and non-addictive drug for the treatment of severe pain

doctor and patient
ATB-352 is designed to treat acute pain as an alternative to highly-addictive opioids

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) is planning to tackle a US$9 billion market with its lead pipeline drug ATB-352.

The Toronto-based company announced Monday that it is targeting the postoperative pain sector with ATB-352, a potent and non-addictive drug for the treatment of severe pain.

The pharmaceutical company is planning to pursue a Fast Track designation with the US Food and Drug Administration to speed up the analgesic’s development and regulatory approval process.

READ: Antibe Therapeutics is poised to disrupt the global pain management industry

“The availability of safe and effective non-opioid therapies for post-operative pain is limited and represents a clear unmet medical need,” said Dan Legault, Antibe’s CEO in a statement.

“Post-operative pain is an ideal indication for ATB-352 given its analgesic potency, gastrointestinal safety and lack of abuse potential. This program has the potential to unlock tremendous value for shareholders, while offering a possible solution to the escalating opioid overdose crisis.”

Antibe said in a statement that it will follow a “step-down” therapeutic strategy for ATB-352 to streamline post-operative pain management in both intravenous and tablet forms for long- and short-term use, respectively.

According to the pharmaceutical company, nearly 50 million people annually who undergo surgeries in the US require post-operative pain medication, and 80% of those patients are prescribed highly addictive opioids.

ATB 352 is a derivative of ketoprofen, a potent NSAID for acute pain. Its intended use will be in competition with strong opioids such as fentanyl and oxycontin.

The company expects to conclude pre-clinical studies in 2020.

Antibe's shares eased 1.5% in Toronto on Monday morning to sit at C$0.32 and rose 3% on OTC markets at US$0.24.

--Updates share price--

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Antibe Therapeutics Inc

Price: 4.85 CAD

Market: TSX
Market Cap: $220.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...


Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read